Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.

<h4>Background</h4>The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. However, TMZ resistance may be one of the main reasons why treatment fails. Although this resistance has frequently been linked to the expression of O6-methylguanine-DNA meth...

Full description

Saved in:
Bibliographic Details
Main Authors: Gloria Perazzoli, Jose Prados, Raul Ortiz, Octavio Caba, Laura Cabeza, Maria Berdasco, Beatriz Gónzalez, Consolación Melguizo
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0140131&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850188998137348096
author Gloria Perazzoli
Jose Prados
Raul Ortiz
Octavio Caba
Laura Cabeza
Maria Berdasco
Beatriz Gónzalez
Consolación Melguizo
author_facet Gloria Perazzoli
Jose Prados
Raul Ortiz
Octavio Caba
Laura Cabeza
Maria Berdasco
Beatriz Gónzalez
Consolación Melguizo
author_sort Gloria Perazzoli
collection DOAJ
description <h4>Background</h4>The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. However, TMZ resistance may be one of the main reasons why treatment fails. Although this resistance has frequently been linked to the expression of O6-methylguanine-DNA methyltransferase (MGMT) it seems that this enzyme is not the only molecular mechanism that may account for the appearance of drug resistance in glioblastoma multiforme patients as the mismatch repair (MMR) complex, P-glycoprotein, and/or the presence of cancer stem cells may also be implicated.<h4>Methods</h4>Four nervous system tumor cell lines were used to analyze the modulation of MGMT expression and MGMT promoter methylation by TMZ treatment. Furthermore, 5-aza-2'-deoxycytidine was used to demethylate the MGMT promoter and O(6)-benzylguanine to block GMT activity. In addition, MMR complex and P-glycoprotein expression were studied before and after TMZ exposure and correlated with MGMT expression. Finally, the effect of TMZ exposure on CD133 expression was analyzed.<h4>Results</h4>Our results showed two clearly differentiated groups of tumor cells characterized by low (A172 and LN229) and high (SF268 and SK-N-SH) basal MGMT expression. Interestingly, cell lines with no MGMT expression and low TMZ IC50 showed a high MMR complex expression, whereas cell lines with high MGMT expression and high TMZ IC50 did not express the MMR complex. In addition, modulation of MGMT expression in A172 and LN229 cell lines was accompanied by a significant increase in the TMZ IC50, whereas no differences were observed in SF268 and SK-N-SH cell lines. In contrast, P-glycoprotein and CD133 was found to be unrelated to TMZ resistance in these cell lines.<h4>Conclusions</h4>These results may be relevant in understanding the phenomenon of TMZ resistance, especially in glioblastoma multiforme patients laking MGMT expression, and may also aid in the design of new therapeutic strategies to improve the efficacy of TMZ in glioblastoma multiforme patients.
format Article
id doaj-art-c22972cc9a014bf7966313c6be2b8d3f
institution OA Journals
issn 1932-6203
language English
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-c22972cc9a014bf7966313c6be2b8d3f2025-08-20T02:15:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011010e014013110.1371/journal.pone.0140131Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.Gloria PerazzoliJose PradosRaul OrtizOctavio CabaLaura CabezaMaria BerdascoBeatriz GónzalezConsolación Melguizo<h4>Background</h4>The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. However, TMZ resistance may be one of the main reasons why treatment fails. Although this resistance has frequently been linked to the expression of O6-methylguanine-DNA methyltransferase (MGMT) it seems that this enzyme is not the only molecular mechanism that may account for the appearance of drug resistance in glioblastoma multiforme patients as the mismatch repair (MMR) complex, P-glycoprotein, and/or the presence of cancer stem cells may also be implicated.<h4>Methods</h4>Four nervous system tumor cell lines were used to analyze the modulation of MGMT expression and MGMT promoter methylation by TMZ treatment. Furthermore, 5-aza-2'-deoxycytidine was used to demethylate the MGMT promoter and O(6)-benzylguanine to block GMT activity. In addition, MMR complex and P-glycoprotein expression were studied before and after TMZ exposure and correlated with MGMT expression. Finally, the effect of TMZ exposure on CD133 expression was analyzed.<h4>Results</h4>Our results showed two clearly differentiated groups of tumor cells characterized by low (A172 and LN229) and high (SF268 and SK-N-SH) basal MGMT expression. Interestingly, cell lines with no MGMT expression and low TMZ IC50 showed a high MMR complex expression, whereas cell lines with high MGMT expression and high TMZ IC50 did not express the MMR complex. In addition, modulation of MGMT expression in A172 and LN229 cell lines was accompanied by a significant increase in the TMZ IC50, whereas no differences were observed in SF268 and SK-N-SH cell lines. In contrast, P-glycoprotein and CD133 was found to be unrelated to TMZ resistance in these cell lines.<h4>Conclusions</h4>These results may be relevant in understanding the phenomenon of TMZ resistance, especially in glioblastoma multiforme patients laking MGMT expression, and may also aid in the design of new therapeutic strategies to improve the efficacy of TMZ in glioblastoma multiforme patients.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0140131&type=printable
spellingShingle Gloria Perazzoli
Jose Prados
Raul Ortiz
Octavio Caba
Laura Cabeza
Maria Berdasco
Beatriz Gónzalez
Consolación Melguizo
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
PLoS ONE
title Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
title_full Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
title_fullStr Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
title_full_unstemmed Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
title_short Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
title_sort temozolomide resistance in glioblastoma cell lines implication of mgmt mmr p glycoprotein and cd133 expression
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0140131&type=printable
work_keys_str_mv AT gloriaperazzoli temozolomideresistanceinglioblastomacelllinesimplicationofmgmtmmrpglycoproteinandcd133expression
AT joseprados temozolomideresistanceinglioblastomacelllinesimplicationofmgmtmmrpglycoproteinandcd133expression
AT raulortiz temozolomideresistanceinglioblastomacelllinesimplicationofmgmtmmrpglycoproteinandcd133expression
AT octaviocaba temozolomideresistanceinglioblastomacelllinesimplicationofmgmtmmrpglycoproteinandcd133expression
AT lauracabeza temozolomideresistanceinglioblastomacelllinesimplicationofmgmtmmrpglycoproteinandcd133expression
AT mariaberdasco temozolomideresistanceinglioblastomacelllinesimplicationofmgmtmmrpglycoproteinandcd133expression
AT beatrizgonzalez temozolomideresistanceinglioblastomacelllinesimplicationofmgmtmmrpglycoproteinandcd133expression
AT consolacionmelguizo temozolomideresistanceinglioblastomacelllinesimplicationofmgmtmmrpglycoproteinandcd133expression